Pharma BD Deal Intelligence
Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug ARV-471 vepdegestrant an oral PROTAC estrogen receptor protein degrader.
Arvinas Form 8-K exhibit: FDA approval of VEPPANU (vepdegestrant), May 1, 2026.
May 12, 2026: Arvinas and Pfizer out-licensed exclusive GLOBAL development, manufacturing and commercialization rights for VEPPANU to Rigel Pharmaceuticals.…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Pfizer and Arvinas entered a global collaboration to develop and commercialize ARV-471 (now vepdegestrant), an oral PROTAC estrogen receptor protein degrader for the treatment of breast cancer. Pfizer paid $650M upfront and Arvinas is eligible for up to $1.4B in milestone payments plus tiered royalties. Development costs and US profits are shared 50/50.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Arvinas, Inc. (this deal) | 2021 | $2.4B | 77 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Pfizer Inc. deals · Oncology deals